Castle Biosciences, Inc. Common Stock
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), uveal melanoma, and mental health conditions. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a risk stratification spatial-omics test to predict future development of progression of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide optimal drug treatment for patients diagnosed with major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. The company offers its products to skin cancer and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Open CSTL dashboard ↗Teleflex Incorporated
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous bone access systems for the administration of intravenous therapies, the measurement of blood pressure, and the collection of blood samples. The company also offers interventional products, including various coronary catheters, structural heart support devices, peripheral intervention products, and mechanical circulatory support platform; and Arrow branded intra-aortic balloon pumps and catheters, Guideliner, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway, pain management, and hemostatic products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligating clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology, as well as bladder management services; and OEM products, which includes the TFX Medical OEM, TFX OEM, Deknatel, and HPC Medical brands. It serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
Open TFX dashboard ↗